Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MESO

Mesoblast Ltd ADR

Mar 25 • 04:00PM ET

14.11

Dollar change -0.28
Percentage change -1.95	%

Healthcare • Biotechnology • Australia • NASD

Peers: BMRN SRPT IONS SGMO BLUE ALNY FATE CARA CYTK KPTI

| Held by: IBB APIE BIB IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.93	Insider Own	-	Shs Outstand	85.82M	Perf Week	7.22%
Market Cap	1.79B	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-	Shs Float	-	Perf Month	-13.06%
Income	-103.11M	PEG	-	EPS next Q	-	Inst Own	2.39%	Short Float	-	Perf Quarter	12.79%
Sales	5.66M	P/S	316.33	EPS this Y	33.56%	Inst Trans	-63.01%	Short Ratio	6.18	Perf Half Y	127.95%
Book/sh	4.00	P/B	3.53	EPS next Y	49.66%	ROA	-15.58%	Short Interest	2.48M	Perf Year	516.16%
Cash/sh	0.30	P/C	47.08	EPS next 5Y	-	ROE	-21.26%	52W Range	2.08 - 22.00	Perf YTD	-28.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	12.34%	ROI	-18.17%	52W High	-35.86%	Beta	3.48
Dividend TTM	-	Quick Ratio	0.63	Sales past 5Y	2.11%	Gross Margin	165.82%	52W Low	578.37%	ATR (14)	0.78
Dividend Ex-Date	-	Current Ratio	0.96	EPS Y/Y TTM	12.87%	Oper. Margin	-912.32%	RSI (14)	43.68	Volatility	3.30% 5.14%
Employees	73	Debt/Eq	0.27	Sales Y/Y TTM	-	Profit Margin	-1822.03%	Recom	1.00	Target Price	25.02
Option/Short	Yes / Yes	LT Debt/Eq	0.23	EPS Q/Q	10.96%	Payout	-	Rel Volume	0.46	Prev Close	14.39
Sales Surprise	7.25%	EPS Surprise	14.29%	Sales Q/Q	-3.91%	Earnings	Feb 26 AMC	Avg Volume	400.70K	Price	14.11
SMA20	-0.33%	SMA50	-14.61%	SMA200	29.76%	Trades		Volume	185,533	Change	-1.95%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-23-24	Downgrade	Jefferies	Buy → Hold
Sep-24-24	Upgrade	Maxim Group	Hold → Buy	$12
Aug-29-24	Upgrade	Jefferies	Hold → Buy
Jul-23-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $11
Aug-31-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Downgrade	Maxim Group	Buy → Hold
Aug-04-23	Downgrade	William Blair	Outperform → Mkt Perform
Aug-04-23	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $2
Mar-09-23	Initiated	William Blair	Outperform	$8
Dec-06-22	Downgrade	Jefferies	Buy → Hold
Sep-06-22	Initiated	Piper Sandler	Overweight	$7
Apr-07-21	Upgrade	Maxim Group	Hold → Buy	$18
Dec-22-20	Downgrade	Maxim Group	Buy → Hold
Dec-04-20	Downgrade	Chardan Capital Markets	Neutral → Sell	$7.50
Oct-22-20	Initiated	RBC Capital Mkts	Sector Perform	$12
Aug-14-20	Reiterated	Maxim Group	Buy	$16 → $22
May-28-20	Reiterated	H.C. Wainwright	Buy	$14 → $21
Jan-31-19	Resumed	H.C. Wainwright	Buy	$6.50
Mar-22-18	Downgrade	Credit Suisse	Neutral → Underperform
Feb-28-18	Reiterated	Cantor Fitzgerald	Buy	$20 → $23

Show Previous Ratings

Mar-13-25 07:42PM	Ryoncil Product Information Now Available in All Four Major Drug Pricing Compendia in United States (GlobeNewswire)
Mar-12-25 07:30AM	Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall (GlobeNewswire)
Mar-06-25 06:54PM	Mesoblast Added to S&P/ASX 200 INDEX (GlobeNewswire) -7.69%
Feb-26-25 05:30PM	Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter (GlobeNewswire)
Feb-25-25 06:13PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
06:33PM	Loading…
Feb-23-25 06:33PM	Dr. Gregory George MD PhD Joins Mesoblast Board (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-13-25 06:37PM	Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings (GlobeNewswire)
Jan-30-25 07:11PM	Ryoncil Commercial Launch Update and Product Pipeline (GlobeNewswire)
06:20PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 (GlobeNewswire)
Dec-19-24 04:21PM	Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval (Investor's Business Daily) +36.82% -12.71%
Dec-18-24 07:08PM	Mesoblast's RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy (GlobeNewswire)
07:30AM	Mesoblast to be Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-05-24 06:29AM	Mesoblasts Revascor Therapy Shows Promise in Heart Failure (TipRanks)
Dec-04-24 06:32PM	FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease (GlobeNewswire)
06:20PM	Loading…
Dec-02-24 06:20PM	Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation (GlobeNewswire)
Nov-14-24 06:37AM	Mesoblast Issues 2 Million Warrants for Strategic Flexibility (TipRanks)
Oct-30-24 07:11PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-19-24 06:30AM	Mesoblast Advances Cellular Medicines Amid FDA Hopes (TipRanks)
Sep-29-24 08:55PM	Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch (GlobeNewswire)
Aug-31-24 05:14PM	10 Best Australian Stocks To Buy According to Hedge Funds (Insider Monkey)
Aug-28-24 07:27PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 (GlobeNewswire)
Aug-27-24 07:25PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Jul-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 (GlobeNewswire)
Jul-23-24 07:53AM	FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire) +9.54%
Jul-21-24 08:45PM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain (GlobeNewswire)
Jul-08-24 08:37PM	Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire)
Jul-02-24 08:04AM	Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates (Zacks)
Jul-01-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
01:55AM	Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week (GlobeNewswire)
08:23PM	Loading…
Jun-02-24 08:23PM	Mesoblast Corporate Presentation at Investor Conference (GlobeNewswire)
Apr-29-24 09:05PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 (GlobeNewswire) +13.78% -7.04%
Mar-30-24 11:49AM	10 Best Long Term ASX Stocks To Invest In (Insider Monkey)
Mar-27-24 11:00AM	Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up (Zacks) -11.20%
Mar-25-24 10:34PM	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire) +78.64%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-13-24 07:30PM	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer (GlobeNewswire) -8.27%
Mar-10-24 07:54PM	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) (GlobeNewswire)
Mar-03-24 08:25AM	Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-28-24 05:57PM	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 (GlobeNewswire) -5.74%
Feb-26-24 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-14-24 07:46PM	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire) +5.96%
Jan-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 (GlobeNewswire)
Jan-19-24 11:30AM	Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug (Zacks) +11.63%
Jan-18-24 06:36PM	United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire)
Nov-27-23 07:28AM	Mesoblast files applications with US FDA for HLHS therapy (Pharmaceutical Business Review)
Nov-26-23 06:56PM	Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease (GlobeNewswire)
Nov-21-23 06:32PM	Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD (GlobeNewswire) +10.74%
Oct-30-23 08:04PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023 (GlobeNewswire) +5.98%
Sep-26-23 06:18AM	Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee (GlobeNewswire)
Sep-22-23 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Sep-21-23 03:30AM	Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval (GlobeNewswire)
Aug-30-23 07:07PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023 (GlobeNewswire) +12.59%
Aug-29-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-04-23 09:38AM	Apple downgraded, Amazon upgraded: Wall Street's top analyst calls (The Fly) -58.90%
Aug-03-23 08:10PM	Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children (GlobeNewswire)
Jul-30-23 08:31PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023 (GlobeNewswire)
Jun-04-23 08:21PM	Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role (GlobeNewswire)
May-25-23 07:28PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023 (GlobeNewswire) +5.22%
May-24-23 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Apr-27-23 09:00PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Apr-25-23 08:47PM	Mesoblast Completes Private Placement (GlobeNewswire)
Mar-21-23 09:20PM	FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing (GlobeNewswire)
Mar-07-23 07:03PM	FDA Accepts Mesoblasts Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023 (GlobeNewswire) -5.90% +23.76%
Feb-27-23 05:13PM	Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022 (GlobeNewswire)
04:49PM	DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC) (GlobeNewswire)
Feb-26-23 07:38PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-16-23 06:16PM	Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy (GlobeNewswire) -7.82%
Feb-08-23 06:09PM	FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain (GlobeNewswire)
Jan-31-23 06:30PM	Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD) (GlobeNewswire) +8.79%
04:40AM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Dec-22-22 07:18PM	Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility (GlobeNewswire)
Dec-15-22 12:00PM	Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know (Zacks) -5.15%
Dec-02-22 03:13PM	Mesoblast Limited's (ASX:MSB) Shift From Loss To Profit (Simply Wall St.)
Nov-23-22 09:38AM	Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease (Benzinga)
Nov-22-22 06:32PM	Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire)
06:01PM	Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022 (GlobeNewswire)
Nov-21-22 06:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire) +5.50%
Oct-30-22 07:50PM	Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022 (GlobeNewswire)
Oct-02-22 07:52PM	Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD (GlobeNewswire)
Aug-30-22 07:05PM	Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022 (GlobeNewswire) +8.42%
Aug-29-22 08:14PM	Mesoblast Corporate Update and Financial Results Webcast (GlobeNewswire)
Aug-18-22 07:00AM	Jane Bell Joins Mesoblast Board (GlobeNewswire)
Jul-29-22 07:05AM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Jul-11-22 08:40PM	Rexlemestrocel-L to be Highlighted at Maxims Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management (GlobeNewswire) -5.12%
Jun-28-22 11:54PM	The past five years for Mesoblast (ASX:MSB) investors has not been profitable (Simply Wall St.)
Jun-23-22 12:05PM	INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL (GlobeNewswire)
Jun-20-22 12:06PM	AVAILABILITY OF THE 2021-2022 UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE COMPOSITION OF THE BOARD OF DIRECTORS, APPOINTMENTS AND REAPPOINTMENTS OF DIRECTORS PROPOSED AT THE SHAREHOLDERS' GENERAL MEETING OF JULY 26, 2022 (GlobeNewswire)
Jun-09-22 07:00AM	Mesoblast Key Opinion Leader Event Series for Investors & Analysts (GlobeNewswire)
May-31-22 08:15PM	Operational Highlights and Financial Results for the Period Ended March 31, 2022 (GlobeNewswire)
May-08-22 08:15PM	Perenti Global (ASX:PRN) shareholders have endured a 44% loss from investing in the stock three years ago (Simply Wall St.)
May-05-22 08:40PM	What Type Of Shareholders Make Up Mesoblast Limited's (ASX:MSB) Share Registry? (Simply Wall St.)
Apr-28-22 08:35PM	Appendix 4C Quarterly Activity Report (GlobeNewswire)
Apr-13-22 10:25AM	BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study (Zacks)
Mar-28-22 09:30PM	Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript (Motley Fool)
Mar-23-22 08:40PM	Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board (GlobeNewswire) -6.92% +6.47%
Feb-27-22 05:18PM	Is Mesoblast (ASX:MSB) Using Debt In A Risky Way? (Simply Wall St.)
Feb-24-22 05:30PM	Operational Highlights and Financial Results for the Period Ended December 31, 2021 (GlobeNewswire)
05:57AM	Mesoblast Corporate Update and Financial Results Webcast (GlobeNewswire)
Feb-20-22 06:19PM	Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohns Colitis After Direct Injection of Remestemcel-L by Colonoscopy (GlobeNewswire)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MESO

Mesoblast Ltd ADR

Upgrade your FINVIZ experience